Jasper Therapeutics (JSPR) Total Current Liabilities (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Total Current Liabilities of $13.2 million for Q4 2025, down 13.37% year-over-year from $15.2 million in Q4 2024, and down 37.27% quarter-over-quarter from $21.0 million in Q3 2025.
Jasper Therapeutics (JSPR) Total Current Liabilities (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $13.2 million for Q4 2025.
- In Q4 2025, Total Current Liabilities fell 13.37% year-over-year to $13.2 million; the TTM figure through Dec 2025 stood at $13.2 million (down 13.37% YoY), while the FY2025 annual figure was $13.2 million, down 13.37% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $13.2 million, down from $21.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $21.0 million in Q3 2025, with the low at $180769.0 in Q1 2021.
- The 5-year median for Total Current Liabilities is $9.1 million (2021), against an average of $10.0 million.
- The sharpest annual moves came in 2021 and 2022: Total Current Liabilities surged 4978.51% in 2021, then retreated 18.98% in 2022.
- Jasper Therapeutics' Total Current Liabilities stood at $8.0 million in 2021, then slipped by 11.91% to $7.1 million in 2022, then soared by 75.15% to $12.4 million in 2023, then climbed by 23.14% to $15.2 million in 2024, then dropped by 13.37% to $13.2 million in 2025.
- Business Quant data shows JSPR's Total Current Liabilities at $13.2 million in Q4 2025, $21.0 million in Q3 2025, and $20.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 630.93 Mn |
| 10 | Jasper Therapeutics | 20.07 Mn | 20.07 Mn | - | 7.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.20 Mn |
| Sep 30, 2025 | 21.04 Mn |
| Jun 30, 2025 | 20.50 Mn |
| Mar 31, 2025 | 12.33 Mn |
| Dec 31, 2024 | 15.24 Mn |
| Sep 30, 2024 | 12.46 Mn |
| Jun 30, 2024 | 10.07 Mn |
| Mar 31, 2024 | 8.92 Mn |
| Dec 31, 2023 | 12.37 Mn |
| Sep 30, 2023 | 11.91 Mn |
| Jun 30, 2023 | 8.97 Mn |
| Mar 31, 2023 | 7.89 Mn |
| Dec 31, 2022 | 7.07 Mn |
| Sep 30, 2022 | 7.42 Mn |
| Jun 30, 2022 | 6.62 Mn |
| Mar 31, 2022 | 5.97 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Sep 30, 2021 | 9.16 Mn |
| Jun 30, 2021 | 328,928.00 |
| Mar 31, 2021 | 180,769.00 |